Key result
Second exposure to eptifibatide during percutaneous coronary intervention was associated with acute profound thrombocytopenia, likely mediated by eptifibatide-induced platelet antibodies.
Why the study?
Does second exposure to eptifibatide cause acute profound thrombocytopenia in patients undergoing PCI?
Case Report (n=1)
Does second exposure to eptifibatide cause acute profound thrombocytopenia in patients undergoing PCI?
Highlights a rare but severe case of immune-mediated acute profound thrombocytopenia following a second exposure to eptifibatide during PCI.
May warrant platelet monitoring on eptifibatide re-exposure in PCI; leaves open incidence and prevention data.
We present a case of eptifibatide-induced acute profound thrombocytopenia in a 64-year-old male receiving eptifibatide for the second time during percutaneous coronary intervention. Although rare, short and self-limited episodes of acute and profound thrombocytopenia have been associated with eptifibatide exposure. The thrombocytopenia is thought to be immune mediated, and assays are available to test for eptifibatide-induced platelet antibodies.
No takes yet. Share an insight, caveat, or question.
Attaya et al. (2009) conducted a case report in Eptifibatide-induced acute profound thrombocytopenia (n=1). Eptifibatide was evaluated on Acute profound thrombocytopenia. Second exposure to eptifibatide during percutaneous coronary intervention was associated with acute profound thrombocytopenia, likely mediated by eptifibatide-induced platelet antibodies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: